The efficacy of bevacizumab, Sorafenib, and retinoic acid on rat endometriosis model

Reproductive Sciences

Volumn 20, Issue 1, 2013, Pages 26-32

  Ozer, Hatice ^a   Boztosun, Abdullah ^a   Açmaz, Gökhan ^b   Atilgan, Remzi ^c   Akkar, Ozlem Bozoklu ^a   Kosar, Mehmet Ilkay ^a  

^a CUMHURIYET UNIVERSITY   (Turkey)

^b Kayseri Training and Education Hospital of Medicine   (Turkey)

^c FIRAT UNIVERSITY   (Turkey)

Author keywords

endometriosis; rat; treatment

Indexed keywords

BEVACIZUMAB; RETINOIC ACID; SORAFENIB; TYROSINE KINASE RECEPTOR; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; ENDOMETRIOSIS; FEMALE; MICROVASCULATURE; NONHUMAN; OVARIAN RESERVE; PRIORITY JOURNAL; RAT; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; DISEASE MODELS, ANIMAL; ENDOMETRIOSIS; FEMALE; MICROVESSELS; NIACINAMIDE; PHENYLUREA COMPOUNDS; RANDOM ALLOCATION; RATS; RATS, WISTAR; TREATMENT OUTCOME; TRETINOIN;

EID: 84870542388     PISSN: 19337191     EISSN: 19337205     Source Type: Journal    
DOI: 10.1177/1933719112452941     Document Type: Article

References (36)

1. Rodgers PA, D'Hooghe TM, Fazleabas A, et al. Priorities for endometriosis research: recommendation from an international consensus workshop. Reprod Sci. 2009 ; 16 (4). 335-346
2. Bondza PK, Mahenx R, Akoum A. Insights into endometriosis-Associated endometrial dysfunctions: a review. Front Biosci (Elite Ed). 2009 ; 1: 415-428
3. Nap AW, Groothuis PG, Demir AY, Evers JLH, Dunselman GAJ. Pathogenesis of endometriosis. Best Pract Res Clin Obstet Gynecol. 2004 ; 18 (2). 233-244
4. Braundmeier AG, Fazleabas AT, Lessey BA, Guo H, Toole BP, Nowak RA. Extracellular matrix metalloproteinase inducer regulates metalloproteinases in human uterine endometrium. J Clin Endocrin Metab. 2006 ; 91 (6). 2358-2365
5. Groothuis PG, Nap AW, Winterhager E, Grümmer R. Vascular development in endometriosis. Angiogenesis. 2005 ; 8 (2). 147-156
6. Donnez J, Smoes P, Gillerot S, Casanas-Roux F, Nisolle M. Vascular endothelial growth factor (VEGF) in endometriosis. Hum Reprod. 1998 ; 13 (6). 1686-1690
7. McLaren J, Prentice A, Charnock-Jones DS, Smith SK. Vascular endothelial growth factor (VEGF) concentrations are elevated in peritoneal fluid of women with endometriosis. Hum Reprod. 1996 ; 11 (1). 220-223
8. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004 ; 350 (23). 2335-2342
9. Grothey A, Ellis LM. Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies. Cancer J. 2008 ; 14 (3). 170-177
10. Young-Hoon Park, Roh SY, Lee YC.. Effect of sorafenib on experimental choroidal neovascularization in the rat. Clin Exp Ophthalmol. 2010 ; 38 (7). 718-726
11. Adnane L, Trail PA, Taylor I, Wilhelm SM. Sorafenib (BAY 43-9006, Nexavar), a dual-Action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Methods Enzymol. 2006 ; 407: 597-612
12. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004 ; 64: 7099-7109
13. Escudier B, Eisen T, Stadler WM, et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol. 2009 ; 27 (20). 3312-3318
14. Tee MK, Vigne JL, Taylor RN. All-trans retinoic acid inhibits vascular endothelial growth factor expression in a cell model of neutrophil activation. Endocrinology. 2006 ; 147 (3). 1264-1270
15. Yucebilgin MS, Terek MC, Ozsaran A, et al. Effect of chemotherapy on primordial follicular reserve of rat: an animal model of premature ovarian failure and infertility. Aust N Z J Obstet Gynaecol. 2004 ; 44 (1). 6-9
16. Basbug M, Bulbuller N, Camci C, et al. The effect of antivascular endothelial growth factor on the development of adhesion formation in laparotomized rats: experimental study. Gastroenterol Res Pract. 2011 ; 2011: 578691
17. Park YH, Roh SY, Lee YC. Effect of sorafenib on experimental choroidal neovascularization in the rat. Clin Experiment Ophthalmol. 2010 ; 38 (7). 718-726
18. O'Dwyer PJ, Ravikumar TS, McCabe DP, Steele G. Effect of 13-cis-retinoic acid on tumor prevention, tumor growth, and metastasis in experimental colon cancer. J Surg Res. 1987 ; 43 (6). 550-557
19. Keenan JA, Williams-Boyce PK, Massey PJ, Chen TT, Caudle MR, Bukovsky A. Regression of endometrial explants in a rat model of endometriosis treated with the immune modulators loxoribine and levamisole. Fertil Steril. 1999 ; 72 (1). 135-141
20. Smith BJ, Plowchalk DR, Sipes IG, Mattison DR. Comparison of random and serial sections in assessment of ovarian toxicity. Reprod Toxicol. 1991 ; 5 (4). 379-383
21. Sharpe-Timms KL. Using rats as a research model for the study of endometrosis. Ann N Y Acad Sci. 2002 ; 955: 318-327
22. Hughes E, Fedorkow D, Collins J, Vandekerckhove P.. Ovulation suppression for endometriosis. Cochrane Database Syst Rev. 2000 ; 2: CD000155
23. Griffioen AW, Molema G. Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol Rev. 2000 ; 52 (2). 237-268
24. Hull ML, Charnock-Jones DS, Chan CL, et al. Antiangiogenic agents are effective inhibitors of endometriosis. J Clin Endocrinol Metab. 2003 ; 88 (6). 2889-2899
25. Becker CM, Sampson DA, Rupnick MA, et al. Endostatin inhibits the growth of endometriotic lesions but does not affect fertility. Fertil Steril. 2005 ; 84 (suppl 2). 1144-1155
26. Papathanassiou M, Theodossiadis PG, Liarakos VS, Rouvas A, Giamarellos-Bourboulis EJ, Vergados IA. Inhibition of corneal neovascularization by subconjunctival bevacizumab in an animal model. Am J Ophthalmol. 2008 ; 145 (3). 424-431
27. Ricci AG, Olivares CN, Bilotas MA, Meresman GF, Barañao RI. Effect of vascular endothelial growth factor inhibition on endometrial implant development in a murine model of endometriosis. Reprod Sci. 2011 ; 18 (7). 614-622
28. Park ACP, Ferin M, Xiao E, Zeitoun K.. Inhibition of endometriosis development in Rhesus monkeys by blocking VEGF receptor: a novel treatment for endometriosis. Fertil Steril. 2004 ; 82:71:
29. Pavone ME, Reierstad S, Sun H, Milad M, Bulun SE, Cheng YH. Altered retinoid uptake and action contributes to cell survival in endometriosis. J Clin Endocrinol Metab. 2010 ; 95 (11). E300 - E309
30. Moraloglu O, Isik H, Kilic S, et al. Effect of bevacizumab on postoperative adhesion formation in a rat uterine horn adhesion model and the correlation with vascular endothelial growth factor and Ki-67 immunopositivity. Fertil Steril. 2011 ; 95 (8). 2638-2641
31. Tee MK, Vigne JL, Taylor RN. All-trans retinoic acid inhibits vascular endothelial growth factor expression in a cell model of neutrophil activation. Endocrinology. 2006 ; 147 (3). 1264-1270
32. Mueller MD, Lebovic DI, Garrett E, Taylor RN. Neutrophils infiltrating the endometrium express vascular endothelial growth factor: potential role in endometrial angiogenesis. Fertil Steril. 2000 ; 74 (1). 107-112
33. Gargett CE, Lederman F, Heryanto B, Gambino LS, Rogers PA. Focal vascular endothelial growth factor correlates with angiogenesis in human endometrium. Role of intravascular neutrophils. Hum Reprod. 2001 ; 16 (6). 1065-1075
34. Na SY, Kang BY, Chung S, et al. Retinoids inhibit interleukin-12 production in macrophages through physical associations of retinoid X receptor and NF kB. J Biol Chem. 1999 ; 274 (12). 7674-7680
35. Bollag W, Majewski S, Jablonska S. Cancer combination chemotherapy with retinoids: experimental rationale. Leukemia. 1994 ; 8 (9). 1453-1457
36. Niikura Y, Niikura T, Wang N, Satirapod C, Tilly JL. Systemic signals in aged males exert potent rejuvenating effects on the ovarian follicle reserve in mammalian females. Aging (Albany NY). 2010 ; 2 (12). 999-1003